QIFENG
873169
LEETRO
430425
KSEC Intelligent Technology
301311
4
Guangdong Topstar Technology
300607
5
Hengerda New Materials
300946
CN Stock MarketDetailed Quotes
688606 Hangzhou Alltest Biotech
- 65.25
- +1.24+1.94%
Market Closed May 12 15:00 CST
5.17BMarket Cap16.22P/E (TTM)
66.41High64.00Low12.30KlotVolume64.74Open64.01Pre Close80.34MTurnover1.55%Turnover Ratio17.10P/E (Static)79.28MShares84.7252wk High1.31P/B5.17BFloat Cap43.7052wk Low76.81Limit Up79.28MShs Float148.07Historical High51.21Limit Down3.77%Amplitude43.09Historical Low3.00Dividend TTM65.30Avg Price5.89KlotAsk4.60%Div YieldTTM100Lot Size5.39KlotBid
Hangzhou Alltest Biotech Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | 0.47%193.36M | 25.09%859.93M | 18.80%586.21M | 16.90%375.51M | 21.13%192.46M | -80.16%687.44M | -82.97%493.44M | -87.45%321.22M | -91.86%158.89M | 71.60%3.47B |
| Refunds of taxes and levies | 244.83%17.86M | 29.92%33.48M | -20.39%15.96M | -21.51%11.75M | 1,241.72%5.18M | -87.27%25.77M | -89.53%20.05M | -89.45%14.97M | -99.58%386.04K | 193.10%202.41M |
| Cash received relating to other operating activities | 23.21%7.7M | -18.87%53.86M | -23.63%35.43M | -19.01%30.99M | -67.03%6.25M | -27.58%66.38M | -36.28%46.39M | -21.94%38.26M | 87.26%18.96M | 124.03%91.66M |
| Cash inflows from operating activities | 7.37%218.92M | 21.51%947.27M | 13.88%637.59M | 11.70%418.26M | 14.40%203.89M | -79.26%779.59M | -82.29%559.87M | -86.39%374.45M | -91.31%178.23M | 76.55%3.76B |
| Goods services cash paid | 32.92%100.88M | -21.83%329.34M | -32.54%227.13M | -39.13%159.9M | -58.74%75.9M | -74.81%421.33M | -77.64%336.71M | -78.88%262.69M | -78.05%183.94M | 97.68%1.67B |
| Staff behalf paid | 5.16%57.49M | 0.17%164.93M | -8.19%128.37M | -25.60%78.88M | 1.43%54.67M | -15.29%164.65M | -7.44%139.82M | -2.38%106.02M | -61.05%53.9M | 71.43%194.36M |
| All taxes paid | 88.33%9.21M | 1.10%41.59M | -65.78%15.5M | -73.01%12.74M | -82.66%4.89M | -85.73%41.13M | -80.94%45.29M | -76.14%47.22M | -56.76%28.21M | 113.86%288.26M |
| Cash paid relating to other operating activities | 38.30%40.59M | -35.88%81.89M | -38.67%74.87M | -18.07%63.98M | -67.34%29.35M | -47.64%127.72M | -53.19%122.08M | -65.47%78.1M | 14.30%89.86M | 118.87%243.93M |
| Cash outflows from operating activities | 26.31%208.18M | -18.16%617.75M | -30.75%445.88M | -36.14%315.51M | -53.69%164.81M | -68.53%754.82M | -70.12%643.9M | -72.19%494.04M | -68.22%355.91M | 98.98%2.4B |
| Net cash flows from operating activities | -72.51%10.75M | 1,230.67%329.52M | 328.15%191.72M | 185.92%102.75M | 122.00%39.08M | -98.18%24.76M | -108.35%-84.03M | -112.27%-119.58M | -119.07%-177.68M | 47.28%1.36B |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | -31.81%587.87M | 35.49%2.4B | 41.51%2B | 3.78%1.4B | 8.86%862.09M | -21.60%1.77B | 6.36%1.41B | 45.96%1.34B | 278.01%791.93M | 188.97%2.26B |
| Cash received from returns on investments | -86.14%599.95K | -75.72%6.97M | 61.97%10.24M | 50.53%9.43M | -7.11%4.33M | 19.64%28.72M | -71.20%6.32M | -67.01%6.26M | 61.98%4.66M | 245.22%24.01M |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | 110,545.43%11.14M | 482.09%1.69M | 43.52%3.27M | 358.34%2.99M | -93.16%10.07K | 1,316.86%290.46K | 342.00%2.28M | 1,104.40%652.67K | --147.17K | 28.69%20.5K |
| Cash received relating to other investing activities | ---- | ---- | ---- | ---- | ---- | ---- | --1.2M | ---- | --585K | ---- |
| Cash inflows from investing activities | -30.80%599.61M | 33.79%2.41B | 41.49%2.01B | 4.17%1.41B | 8.67%866.43M | -21.16%1.8B | 5.32%1.42B | 43.74%1.35B | 275.43%797.32M | 189.46%2.28B |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | 18.79%83.89M | -58.64%220.65M | -61.69%177.49M | -52.39%126.37M | -39.81%70.62M | 97.41%533.49M | 139.36%463.26M | 81.02%265.43M | 136.04%117.32M | 92.86%270.24M |
| Cash paid to acquire investments | -36.91%550.2M | 88.14%2.64B | 119.36%1.99B | 141.21%1.64B | 45.34%872.06M | -56.86%1.41B | -54.39%905.35M | -50.72%680.1M | 173.94%600M | 176.29%3.26B |
| Net cash paid to acquire subsidiaries and other business units | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --16.61M |
| Cash paid relating to other investing activities | ---- | --20M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash outflows from investing activities | -32.73%634.09M | 48.79%2.88B | 58.08%2.16B | 86.86%1.77B | 31.42%942.68M | -45.30%1.94B | -41.14%1.37B | -43.49%945.53M | 166.93%717.32M | 168.69%3.54B |
| Net cash flows from investing activities | 54.78%-34.48M | -240.56%-479.06M | -381.92%-151.2M | -188.24%-358.6M | -195.32%-76.25M | 88.87%-140.67M | 105.50%53.63M | 155.46%406.39M | 241.95%80M | -137.88%-1.26B |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | ---- | 100.71%401.43K | -99.29%1.42K | -99.29%1.42K | ---- | -94.59%200K | -94.59%200K | -94.59%200K | -95.45%200K | -99.78%3.7M |
| -Including: Cash received from capital contributions by minority shareholders of subsidiaries | ---- | 100.71%401.43K | -99.29%1.42K | -99.29%1.42K | ---- | -94.59%200K | -94.59%200K | -94.59%200K | --200K | --3.7M |
| Cash received relating to other financing activities | ---- | -1.89%8.57M | -71.71%2.47M | ---- | ---- | --8.74M | --8.74M | ---- | ---- | ---- |
| Cash inflows from financing activities | ---- | 0.40%8.97M | -72.33%2.47M | -99.29%1.42K | ---- | 141.54%8.94M | 141.54%8.94M | -94.59%200K | -98.91%200K | -99.78%3.7M |
| Dividend interest payment | ---- | -55.99%232.66M | -78.00%116.29M | -90.51%50.17M | ---- | 145.20%528.7M | 145.20%528.68M | 145.20%528.68M | ---- | 100.00%215.62M |
| Cash payments relating to other financing activities | ---- | 25.66%49.04M | 7.79%41.79M | 335.17%39.82M | 365.12%39.52M | -73.98%39.03M | -74.09%38.77M | -58.57%9.15M | -22.21%8.5M | 188.34%149.99M |
| Cash outflows from financing activities | ---- | -50.38%281.71M | -72.14%158.08M | -83.27%89.98M | 365.12%39.52M | 55.28%567.73M | 55.37%567.45M | 126.27%537.83M | -23.81%8.5M | 128.75%365.61M |
| Net cash flows from financing activities | ---- | 51.19%-272.73M | 72.14%-155.61M | 83.26%-89.98M | -376.34%-39.52M | -54.40%-558.79M | -54.48%-558.52M | -129.76%-537.63M | -214.74%-8.3M | -123.81%-361.91M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | -892.52%-365.49K | -36.92%5.98M | -144.23%-5.44M | -88.51%2.03M | 100.73%46.12K | -86.03%9.48M | -78.61%12.29M | -48.20%17.66M | -4.79%-6.34M | 462.43%67.86M |
| Net increase in cash and cash equivalents | 68.55%-24.1M | 37.42%-416.29M | 79.10%-120.53M | -47.45%-343.8M | 31.76%-76.64M | -237.05%-665.22M | -111.38%-576.62M | -655.43%-233.17M | -112.81%-112.31M | -110.42%-197.36M |
| Add:Begin period cash and cash equivalents | -31.62%900.34M | -33.57%1.32B | -33.57%1.32B | -33.57%1.32B | -33.57%1.32B | -9.06%1.98B | -9.06%1.98B | -9.06%1.98B | -9.12%1.98B | 663.19%2.18B |
| End period cash equivalent | -29.34%876.23M | -31.62%900.34M | -14.88%1.2B | -44.37%972.82M | -33.67%1.24B | -33.57%1.32B | -26.29%1.41B | -21.27%1.75B | -38.85%1.87B | -9.06%1.98B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | -- | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.